What makes OCA the right call over other repair options

Is OCA the right repair for a large knee defect? For most patients, the question turns on two things: the size of what has been lost, and whether the damage goes deeper than cartilage.

Osteochondral allograft transplantation — OCA — works by implanting a matched plug of fresh donor tissue that carries both the articular cartilage surface and the underlying subchondral bone as a single unit. That distinction matters. Procedures such as MACI or AMIC rebuild the cartilage layer but cannot restore the bony scaffold beneath it; when the subchondral bone is eroded or fractured, those techniques face a compromised foundation. OCA replaces both layers in a single operation.

Size is the other defining factor. OCA is designed for focal, full-thickness (ICRS Grade 3–4) defects typically exceeding 2–4 cm². For lesions larger than 6 cm², cell-based options are generally insufficient, and OCA becomes the primary surgical choice. Autograft transfer (OATS or mosaicplasty), by contrast, is constrained by the size of plugs that can be harvested from the patient's own joint — typically viable only up to around 4 cm² before donor-site morbidity becomes prohibitive.

Aetiology also shapes the decision. Post-traumatic defects — those following an injury rather than gradual joint-wide wear — carry a meaningfully better prognosis for graft integration than lesions arising from degenerative change.

OCA sits at the third stage of the cartilage care pathway: after conservative measures and biologic support have been explored, but with the explicit aim of delaying or avoiding joint replacement rather than offering a permanent cure.

Candidacy: who OCA works best for

Several factors converge to make someone a strong OCA candidate — and understanding them in combination matters more than any single criterion in isolation.

Defect characteristics

The lesion itself needs to meet a few structural requirements. Grade 3–4 full-thickness damage with subchondral bone involvement is the typical starting point, and in published series the mean allograft area transplanted has been around 6.4 cm², with lesions grouped broadly as small (<5 cm²), medium (5–8 cm²), or large (>8 cm²). The cartilage surrounding the defect must provide a stable containment rim — at least 50–75% of the circumference intact — so the graft can seat and integrate properly. Without that rim, mechanical support for the plug is insufficient regardless of the patient's other characteristics.

Patient profile

The ideal surgical candidate is typically under 40–50 years old, active, and presenting with a focal post-traumatic lesion rather than one arising from diffuse degenerative change. Age matters in practice: patients under 40 consistently record better KOOS symptom scores post-operatively than older cohorts in published series, and younger patients carry lower graft failure rates overall.

Femoral condyle lesions — particularly the medial condyle — have the strongest outcome evidence. Patellofemoral and tibial-side defects can be treated with OCA, but results are somewhat less predictable, and patients should be counselled on that distinction before proceeding.

Concurrent pathology

Malalignment, ligamentous instability, and meniscal deficiency are not secondary concerns to be deferred — they must be corrected at or before the OCA procedure. Placing a graft into a mechanically hostile environment significantly undermines the chances of durable integration. Where an osteotomy or ligament reconstruction is needed, the surgical plan addresses these jointly rather than sequentially.

Contraindications and relative barriers to OCA

Not every patient with a large cartilage defect will be suited to OCA, and understanding where the boundaries lie — and whether they are firm or context-dependent — is part of making a well-informed decision.

Several contraindications are absolute. Active joint infection, inflammatory joint disease (such as rheumatoid arthritis), and end-stage or diffuse osteoarthritis rule out OCA in all circumstances: the procedure requires a biologically receptive host environment, and none of these conditions provides one. Uncorrected limb malalignment or ligament instability — where correction is not planned as part of the surgical episode — is similarly prohibitive, given the strong association between a mechanically hostile environment and early graft failure. A BMI above 35 kg/m² is a consistent exclusion across clinical-policy frameworks. Tobacco use, alcohol misuse, and a history of malignancy are also listed as contraindications in published criteria.

Bipolar cartilage loss — where opposing surfaces on both sides of the joint are damaged — significantly worsens prognosis and generally sits outside OCA's indication scope.

Age above 49–50 is a relative rather than absolute barrier. Payer criteria commonly cite this threshold, yet some older patients with truly isolated focal wear on an otherwise structurally healthy joint may still be appropriate candidates after careful specialist review.

Where the picture is unclear, formal assessment is the proper route to an individual answer.

How long OCA grafts last: the survivorship evidence

The survivorship data across multiple independent series tells a broadly consistent story — and for most patients the trajectory is considerably more durable than they might expect.

The most recent major systematic review (Haikal et al., 2023) provides the clearest decade-by-decade picture: graft survival of 86.7% at five years, 78.7% at ten years, 72.8% at fifteen years, and 67.5% at twenty years. NHS England's 2022 evidence review, drawing on a wider set of series, brackets the five-year figure more broadly at 82–97%, with convergence to approximately 69% at the twenty-year mark — consistent with Haikal's upper range. Across these sources the curves do not fall sharply; they trace a gradual, moderate decline rather than a cliff edge.

The landmark Assenmacher 2016 systematic review — 202 citations, mean follow-up of 12.3 years — found 75% successful outcomes overall, a figure that has held up as subsequent series have accumulated. At the far end of available follow-up, Raz et al. (JBJS 2014) confirmed that distal femoral fresh allografts remained durable at a mean of 22 years, the longest reported series in the literature.

Critically, the dominant failure mode matters as much as the failure rate itself. Approximately 72% of OCA failures represent conversion to partial or total knee arthroplasty — not biological rejection, not graft collapse, not infection. For most patients, the graft eventually 'fails' by doing precisely what joint-preservation surgery intends: providing years of symptom-free function before the knee ultimately needs a replacement it was always going to need.

For patients who have already undergone OCA, Bi et al. (2025) found that gains in patient-reported outcomes at two years reliably predict sustained improvement at mid- and long-term follow-up — offering a useful early prognostic window.

Return to sport and functional recovery

Across published series, roughly three in four patients return to sport or recreational activity following OCA — a figure drawn from a cohort of 149 knees at a mean follow-up of six years, in which 75.2% (112 knees) had resumed their chosen activity. On IKDC-based evaluation of the same cohort, 71% rated their knee function as 'very good' to 'excellent', and 79% were participating in moderate-to-very strenuous activities. These are meaningful benchmarks: the IKDC instrument captures both pain relief and physical capacity, so the figures reflect functional recovery in a practical sense, not simply symptom reduction on paper.

Those aggregate results conceal variation that matters for individual counselling. As established in the candidacy discussion, age at surgery and lesion location are both significant — patients under 40 tend to achieve better KOOS symptom scores, and femoral condyle OCA delivers more consistent results than patellofemoral OCA. For patients with kneecap-side damage, the data point to a more variable return-to-sport trajectory: this is an honest signal about prognosis, not a reason to dismiss OCA as an option.

On timing, the evidence does not support a fixed month-by-month recovery schedule, and the variation between lesion sizes, locations, and concurrent procedures is too wide for a single figure to be useful. Most published series report meaningful functional return within the first one to two years post-surgery; more demanding sporting levels can take longer to reach. The six-year follow-up data suggest that functional gains, once established, are durable rather than transient.

Graft access, evidence limitations, and getting assessed

Honest appraisal of OCA includes two categories of constraint: logistical and evidential.

On logistics, fresh allograft scheduling is time-sensitive. Chondrocyte viability declines progressively after procurement and falls below the broadly accepted 70% threshold by approximately Day 28, which means surgical timing cannot always be arranged at the patient's or surgeon's convenience — graft availability and viable processing windows shape when, and whether, a suitable plug can be matched and prepared in time.

The evidence base carries geographic caveats worth acknowledging. The overwhelming majority of long-term series originate from a handful of specialist academic centres — principally the Bugbee, Gross, and Cole groups in North America. Both Haikal et al. (2023) and the NHS England 2022 evidence review draw substantially on these cohorts. How those outcomes translate to routine practice settings, or to the UK specifically, is not established by independent long-term registry data.

Evidence is also thinner for certain anatomical configurations: bipolar lesions (where both opposing joint surfaces are damaged), tibial-side defects, and complex multi-compartment cases carry sparser outcome data than isolated femoral condyle OCA. And direct comparative data against MACI, ACI, or OATS in matched large-defect cohorts remain limited — technique selection rests principally on defect characteristics, patient profile, and surgical expertise rather than head-to-head trial evidence.

For patients in the UK, establishing whether OCA or an alternative approach fits their specific case is a matter for specialist joint-preservation assessment; that kind of structured evaluation can be arranged via londoncartilage.com.